Article
Clinical Neurology
Katharina Schiller, Saoussen Berrahmoune, Christelle Dassi, Isabelle Corriveau, Taghreed A. Ayash, Bradley Osterman, Chantal Poulin, Michael Shevell, Elisabeth Simard-Tremblay, Guillaume Sebire, Kenneth A. Myers
Summary: This randomized double-blind placebo-controlled crossover trial showed that memantine is a safe and effective treatment for children with developmental and epileptic encephalopathy, improving both seizure control and cognitive function.
Article
Endocrinology & Metabolism
Chao Wang, Yaqiong An, Zhaohua Xia, Xuezhi Zhou, Haibo Li, Shuang Song, Lexi Ding, Xiaobo Xia
Summary: This study found that melatonin could protect RGCs from glutamate excitotoxicity and NMDA-induced injury, reduce oxidative stress, and improve visual function in mice. These findings provide practical research ideas for the comprehensive prevention and treatment of glaucoma using melatonin.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Cell Biology
Ying Hao, Rui Xiong, Xue Gong
Summary: The study demonstrated that memantine (MEM) can alleviate inflammation, oxidative stress, and apoptosis induced by atherosclerosis by activating the BDNF/TrkB signaling pathway in HUVECs.
Article
Neurosciences
Devaraj Basavarajappa, Vivek Gupta, Nitin Chitranshi, Deepa Viswanathan, Veer Gupta, Roshana Vander Wall, Viswanthram Palanivel, Mehdi Mirzaei, Yuyi You, Alexander Klistorner, Stuart L. Graham
Summary: Glaucoma is a major cause of permanent blindness worldwide, characterized by neurodegeneration and neuroinflammation. Siponimod, an immunomodulatory drug, has shown protective effects against acute NMDA excitotoxicity in the retina. Activation of glial cells, inflammatory pathways, and the NLRP3 inflammasome were suppressed with siponimod treatment. These findings suggest that siponimod has anti-inflammatory effects and could be a potential therapeutic strategy for neuroinflammatory conditions.
MOLECULAR NEUROBIOLOGY
(2023)
Article
Clinical Neurology
Chiara Montemitro, Alexandra Angebrandt, Tzu-Yun Wang, Mauro Pettorruso, Osama A. Abulseoud
Summary: Memantine has shown efficacy in reducing alcohol and opiate cravings, consumption, and withdrawal severity, but not significant effect on cocaine and nicotine use disorders. Possible mechanisms behind this variability need further study for a better understanding of its efficacy in treating drug addiction.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Neurosciences
Ignazia Mocci, Maria Antonietta Casu, Valeria Sogos, Anna Liscia, Rossella Angius, Francesca Cadeddu, Maura Fanti, Patrizia Muroni, Giuseppe Talani, Andrea Diana, Maria Collu, Maria Dolores Setzu
Summary: This study investigated the anti-manic properties of the NMDA receptor antagonist memantine in a fruit fly model of bipolar disorder and found that memantine can improve behavioral abnormalities and reduce glutamate receptor overexpression. The results suggest that the fruit fly model is a promising tool for studying the neurobiology of bipolar disorders. Memantine may be a disease-modifying therapy with new mechanisms of action.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Pharmacology & Pharmacy
Vahid Shafiei-Irannejad, Samin Abbaszadeh, Paul M. L. Janssen, Hamid Soraya
Summary: Memantine is a non-competitive NMDA receptor antagonist used for Alzheimer's disease and potentially other pathologies. Research suggests that glutamate signaling may play a role in cancer progression. Additionally, NMDA receptors are being studied in relation to cardiovascular disorders.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Review
Neurosciences
Diego Pichardo-Rojas, Pavel Salvador Pichardo-Rojas, Jose Manuel Cornejo-Bravo, Aracely Serrano-Medina
Summary: The primary mechanism for neuron death after an ischemic stroke is excessive depolarization leading to NMDA-mediated calcium entry and subsequent cellular death. Memantine, a non-competitive NMDA receptor antagonist, has shown promising preclinical and clinical evidence as a neuroprotective drug for ischemic stroke. Clinical trials have found that high-dose memantine can improve neurological function and aphasia in poststroke patients, but limitations such as small sample sizes limit the impact of these findings. Further research is needed to conclusively determine if memantine improves outcomes in patients post-ischemic stroke.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Neurosciences
Maxim Nikolaev, Anton Chizhov, Denis B. Tikhonov
Summary: The study compared the effects of different NMDAR antagonists on epileptiform activity induced by picrotoxin in rat brain slices. The results showed that memantine had a stronger inhibitory effect on PDS in fast-spiking interneurons (FSI) compared to pyramidal cells (PC), which could be explained by the use dependence of its action.
Review
Pharmacology & Pharmacy
Karolina Podkowa, Kamil Czarnacki, Agnieszka Boronczyk, Michal Boronczyk, Justyna Paprocka
Summary: Migraine, a disorder that affects females more often than males, may be treated with NMDA receptor antagonists such as memantine and ketamine, according to a comprehensive literature review. Animal and in vitro studies have shown that these drugs inhibit the propagation of spreading depression (SD), a major mechanism in migraine pathophysiology. Clinical trials have also indicated that ketamine or memantine may be effective in treating severe migraine, although more studies with control groups are needed. These drugs could be a promising alternative for individuals with treatment-resistant migraine with aura or limited treatment options.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2023)
Article
Neurosciences
Kenan Yildizhan, Mustafa Naziroglu
Summary: TRPM2 channel is activated by excessive generation of mitochondrial and cytosolic ROS and influx of intracellular free Ca2+. The inhibitions of NMDA receptor and TRPM2 channel decrease ROS and apoptosis in neurons. The modulator role of memantine and NMDA via modulation of TRPM2 on oxidative neurodegeneration and apoptosis in SH-SY5Y cells was investigated. Inhibition of NMDA receptor via memantine treatment modulated HYP-mediated ROS, apoptosis, and TRPM2-induced excessive Ca2+ and may provide a strategy for protecting HYP-mediated neurodegenerative diseases.
Article
Neurosciences
Xuejin Zhang, Rong Zhang, Jihong Wu
Summary: This study investigates the involvement of the NR2B-PSD95 complex in glaucoma and finds that it plays a role in RGC death. Disrupting the NR2B-PSD95 interaction through drug intervention exerts a neuroprotective effect on RGCs.
Article
Ophthalmology
Max K. Colbert, Leon C. Ho, Yolandi van der Merwe, Xiaoling Yang, Gillian J. McLellan, Samuel A. Hurley, Aaron S. Field, Hongmin Yun, Yiqin Du, Ian P. Conner, Carlos Parra, Muneeb A. Faiq, John H. Fingert, Gadi Wollstein, Joel S. Schuman, Kevin C. Chan
Summary: Using diffusion tensor imaging (DTI), this study characterized the visual pathway integrity of five glaucoma animal models, revealing that chronic IOP elevation resulted in decreased fractional anisotropy and increased radial diffusivity along the optic nerve or optic tract. Variation in axial diffusivity effects between models suggests different aspects of pathological changes over time and with severity.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2021)
Article
Ophthalmology
Aidan B. Jackson, Keith R. Martin, Michael A. Coote, Felipe A. Medeiros, Christopher A. Girkin, Massimo A. Fazio, Jeffrey M. Liebmann, Carlos Gustavo De Moraes, Robert N. Weinreb, Linda M. Zangwill, Zhichao Wu
Summary: The purpose of this study was to determine the prevalence of fast global and central visual field progression in glaucoma patients under routine care. The findings revealed that approximately 1 in 8 eyes with glaucoma receiving routine care showed fast progression based on global mean deviation (MD) values (< -1.0 dB/year), and nearly 1 in 3 eyes exhibited a decline of < -0.5 dB/year centrally. These findings emphasize the clinical importance of assessing progressive central visual field loss and the need for new therapies to prevent functional disability in a notable proportion of patients showing fast progression.
Article
Medicine, General & Internal
Dariusz Swietlik, Aida Kusiak, Marta Krasny, Jacek Bialowas
Summary: In this study, mathematical and computer modelling of excitotoxicity phenomenon and virtual memantine therapy were performed. The results showed that memantine has significant neuroprotective benefits in patients with moderate to severe Alzheimer's disease, particularly in the area of memory. However, memantine only provides symptomatic and temporary support for AD patients, highlighting the need for further research into new drugs for AD treatment.
JOURNAL OF CLINICAL MEDICINE
(2022)